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nulus distortion or perioperative morbidity as
reported by Dr Aazami.
Although the findings of Lomhlot and
associates6 contradict the statements of Kun-
zelman and Cochran,7 the results of Messas
and colleagues8 are more consistent with the
major role of stress generated by primary
chordae in comparison with the secondary
ones. In addition, the intact marginal chordae
continue to prevent leaflet prolapse or failure
and can, theoretically, continue to maintain
left ventricular function through chordal con-
tinuity as a benefit of valve repair as opposed
to replacement.9,10 In our experience, the
chordal cutting procedure did not impair the
midterm (3 years’ follow-up) left ventricular
function, as shown by the absence of MR at
rest and mild MR on exertion (Figure 1, C
and D).
Finally, this report has reopened the de-
bate regarding a very difficult question that
continually challenges cardiologists and sur-
geons. Indeed, the optimal surgical treatment
of ischemic MR in patients with varying de-
grees of MR and coronary artery disease is
controversial. The complex pathophysiology
and heterogeneous clinical presentation of
this group of patients could be an explanation
for this controversy. The answer could be
provided by wide, controlled, randomized
studies comparing CABG associated with
mitral valve plasty by chordal cutting with or
without annuloplasty.
G. Fayad, MD
T. Modine, MD
H. Warembourg, MD
Hôpital Cardiologique
CHRU de Lille, France
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Early anticoagulation after
aortic valve replacement with
bioprostheses: Time to abandon it?
To the Editor:
According to the American College of
Cardiology/American Heart Association
(ACC/AHA) Guidelines for Valvular Heart
Disease,1 a 3-month-long program of anti-
coagulation therapy is recommended after
valve replacement with tissue valves. On
the contrary, a recent study carried out by
the Cardiothoracic Surgery Network (CTS-
Net) Valve Technology Center, “The An-
ticoagulation Therapy and Valve Replace-
ment Study,”2 has outlined that the practice
tends to diverge from the widely estab-
lished guidelines. In fact, 80% of 726 par-
ticipating surgeons prefer to adopt anti-
platelet therapy in biologic valve recipients
who do not have additional risk factors for
thromboembolic events.
Sundt and associates3 have demon-
strated in 624 patients that anticoagulant
therapy after aortic valve replacement
(AVR) did not offer advantages in terms of
neurologic morbidity compared with 527
patients who did not receive warfarin.
Similarly, at our institution, the policy
currently adopted is to administer aspirin
despite warfarin during the 3-month time
interval necessary for the sewing ring to
become completely endothelialized. Anti-
coagulants remain indicated in the presence
of comorbidities that leave the patient at
risk for thromboembolism, such as chronic
atrial fibrillation, atriomegaly, severe im-
pairment of left ventricular function, and
ventricular aneurysms.
Nevertheless, we share the concerns
raised by the CTSNet. In fact, currently
there is no clear evidence that this alterna-
tive approach is free from neurologic det-
rimental effects. We believe that the satis-
factory clinical results in terms of
cerebrovascular accidents reported by
Sundt and coworkers3 cannot exclude the
possibility of asymptomatic microemboli-
zation and that mere clinical evaluation
might be limited.
At our institution, to overcome a potential
underestimation related to sheer clinical ob-
servations, we decided to evaluate the occur-
rence of microembolic signals (MES) in pa-
tients after heart valve replacement surgery
by transcranial Doppler. Our preliminary re-
sults in 58 patients (43 men and 15 women,
mean age 69.8 years) undergoing tissue valve
replacement (23 patients) versus mechanical
valve replacement (35 patients) let us draw a
correlation between the absence of clinical
neurologic impairment (0% of neurologic
complications) and the absence of MES in
the subcohort of aortic biologic valve patients
who received aspirin instead of warfarin in
the early postoperative period (0% of MES at
transcranial Doppler). On the basis of these
preliminary results, we set out on a prospec-
tive clinical trial randomizing patients, after
AVR, for antiplatelet versus anticoagulant
early therapy. The postoperative evaluation
pursued in the trial, which is ongoing, is both
clinical and instrumental, aiming to detect
potential clinically silent microembolization.
We believe that the positive clinical re-
sults encountered by Sundt and associates3
and shared also by our experience need
instrument-based evidence to represent a
firm basis and efficacious stimulus toward
reconsideration of guidelines.
Francesca di Marco, MDa
Giorgio Meneghetti, MDb
Gino Gerosa, MDa
Institute of Cardiovascular Surgerya
Neurology Divisionb
Padua University Medical School
Padova, Italy
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Atrial septal defect in infancy:
To close or not to close?
To the Editor:
I read with great interest the article by
Lammers and associates1 advocating that
closure of an atrial septal defect (ASD)
should not be postponed to a later age if
clinical problems that can be attributed at
least in part to the ASD are present. How-
ever, a closer look at the historical cohort
of Lammers and associates reveals that it is
composed mainly of premature syndromic
infants in whom the major issue is bron-
chopulmonary dysplasia and pulmonary
hypertension rather than left-to-right shunt
across the ASD.2 Hence the suggestion of
the authors, in the opinion of this reader, is
controversial.
Although ASD is the second most com-
mon congenital heart disease in children,3
there are still few unanswered questions
related to the appropriate timing of closure.
Because patients with even large ASDs are
mostly asymptomatic, closure is recom-
mended around 3 to 5 years of age, before
the child goes to school. Postponing surgi-
cal intervention to this age also allows for
spontaneous closure of the ASD in some
children.4 In fact, there does not appear to
be any significant benefit in ASD closure
before 3 to 5 years of age in small- to
moderate-sized defects.5
In the opinion of this reader, in the
present era of better ventilator equipment
and styles of ventilator management, along
with widespread use of corticosteroids pre-
natally and surfactant, nitric oxide, and pul-
monary vasodilator therapy postnatally,
surgical ASD closure can be postponed in
patients with compromised lung function
unless all available means of improving
lung function have been tried. Only when
pulmonary compromising factors have
been corrected will an attempt at surgical
ASD closure in infancy be valid because
even though mortality for major operations
with cardiopulmonary bypass in infants
with low weight has become low, a definite
morbidity still persists.
Shahzad G. Raja, MRCS
Department of Cardiac Surgery
Royal Hospital for Sick Children
Yorkhill NHS Trust
Dalnair St
Glasgow G3 8SJ
United Kingdom
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Reply to the Editor:
We appreciate Dr Raja’s interest in our
recent study.1
We agree that in asymptomatic children
closure of an isolated secundum-type atrial
septal defect (ASD II) should be under-
taken after 4 to 5 years of age because this
might allow for spontaneous closure and
facilitate interventional closure in some pa-
tients. However, we describe a specific
group of patients in whom symptoms have
been at least in part related to the presence
of an ASD II. In these patients with com-
promised lungs and rarefied pulmonary
vasculature, even a minor left-to-right
shunt is poorly tolerated, and early surgical
closure could be beneficial.
Our catheter data showed that the ma-
jority of the children had a left-to-right
shunt that varied in magnitude, as is dem-
onstrated by the Qp/Qs ratio. The actual
effect of the left-to-right shunt on the in-
fant’s clinical condition is difficult to as-
sess. However, the ASD is an additional
factor compromising the child’s situation.
One cannot treat lung hypoplasia or severe
chronic lung disease, but an ASD is ame-
nable to treatment.
There might be a subgroup of patients
in whom closure of an ASD is contraindi-
cated. In the presence of progressive pul-
monary vascular disease, the existence of
an ASD can improve survival.2
Dr Raja suggests that surgical ASD clo-
sure in infancy should only be performed
after all other compromising factors are
corrected. Yet even in the current era of
better ventilator management and use of
antenatal corticosteroids, nitric oxide, and
surfactant leading to improved survival of
infants, correction of the lung-compromising
factors is not always possible. Moreover,
long-term hospitalization and prolonged
ventilation of these children is associated
with substantial morbidity, including baro-
trauma, hospital-acquired infections, and
immobilization. Therefore we contend that
a subgroup of infants can indeed benefit
from early ASD closure. Careful patient
selection, however, remains a clinical chal-
lenge and requires a multidisciplinary ap-
proach involving cardiologists, intensivists,
and cardiothoracic surgeons to determine
the right timing of ASD closure for each
individual child.
Astrid Lammers
John Hess, MD, FESC
Klinik für Kinderkardiologie und angeborene
Herzfehler
Deutsches Herzzentrum München
Technische Universität München
Munich, Germany
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The evaluation of aortic
atherosclerosis and distensibility in
aortic valve stenosis—The role of
transesophageal echocardiography
To the Editor:
We read with great interest and congratulate
Weisenberg and associates on their trans-
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